Related Experiment Video
Updated: Apr 11, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Risk stratification in extramammary Paget disease
J M Cohen1, S R Granter2, A E Werchniak3,4
1Harvard Medical School, Boston, MA, USA.
Extramammary Paget disease (EMPD) risk stratification is aided by understanding prognostic factors like invasion depth and extracutaneous spread. Emerging data on tumor genetics also aids in assessing Extramammary Paget disease (EMPD) prognosis.
Area of Science:
- Oncology
- Dermatology
Background:
- Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting apocrine gland-rich areas.
- Risk stratification and treatment planning for EMPD present clinical challenges.
Purpose of the Study:
- To review prognostic factors for Extramammary Paget disease (EMPD).
- To assist physicians in risk stratifying EMPD patients.
Main Methods:
- Review of existing literature on Extramammary Paget disease (EMPD) prognostic indicators.
- Analysis of data on depth of invasion, extracutaneous involvement, and tumor genetics (Ki-67, cyclin D1, Mucin 5AC, E-cadherin).
Main Results:
- Tumor invasion into the reticular dermis or depth > 1 mm indicates poorer prognosis.
- Extracutaneous spread (lymph nodes, other tissues) signifies higher risk.
- Tumor genetics show emerging importance, while lesion site and patient age have less evidence.
Conclusions:
- Depth of invasion and extracutaneous involvement are key prognostic factors in EMPD.
- Tumor genetics are increasingly recognized for their role in EMPD risk stratification.
- This review provides valuable information for clinical practice and EMPD research.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
06:06High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024